SCHEMBL23213997

SCHEMBL23213997

CCOC(=O)c1cc(Br)nn1C1CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 1/20 0.37
ELANE P08246 1/20 0.37
GRK6 P43250 1/20 0.37
PLAT P00750 1/20 0.37
FAAH O00519 2/20 0.36
ALDH1A1 P00352 2/20 0.36
PDE7A Q13946 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
MAPK1 P28482 1/20 0.36
OPRK1 P41145 1/20 0.36
RAB9A P51151 1/20 0.36
PDE5A O76074 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16244656 0.85 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2MAPTPOLBGRK6
SCHEMBL27256369 0.84 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2MAPTPOLBGRK6
SCHEMBL20944278 0.84 KMT2A (0.40) KMT2ASMN1; SMN2POLBGRK6FAAH
SCHEMBL23213685 0.84 KCNH2 (0.37) KMT2APLATALDH1A1OPRK1
SCHEMBL26976579 0.81 KMT2A (0.40) KMT2ASMN1; SMN2POLBGRK6ALDH1A1
SCHEMBL25399863 0.80 KMT2A (0.46) KMT2ASMN1; SMN2MAPTPOLBELANE
SCHEMBL9681221 0.80 KMT2A (0.44) KMT2ASMN1; SMN2MAPTPOLBFAAH
SCHEMBL16244787 0.80 KMT2A (0.41) KMT2AMAPTPLATALDH1A1MAPK1
SCHEMBL22637871 0.80 HSD17B10 (0.40) KMT2ASMN1; SMN2MAPTPOLBGRK6
SCHEMBL16344633 0.79 KMT2A (0.48) KMT2ASMN1; SMN2MAPTPOLBFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114630822-B Biaryl dihydroorotate acid dehydrogenase inhibitors 詹森生物科技公司 2024-10-01 CN disclosed
US-20240158414-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. 2024-05-16 US disclosed
EP-4041714-B1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-12-13 EP disclosed
EP-4041714-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS Janssen Biotech, Inc. (US) 2022-08-17 EP disclosed
CN-114630822-A Biaryl dihydroorotate dehydrogenase inhibitors 詹森生物科技公司 2022-06-14 CN disclosed
WO-2021070132-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158414-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, DLD, DPYD KMT2A 1788/4885SMN1; SMN2 3813/4885MAPT 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.